Novavax stock soars

Novavax stock soars as FDA removes clinical hold on its COVID and influenza shot
Investing.com -- The U.S. Food and Drug Administration (FDA) has lifted its hold on a late-stage trial for Novavax’s COVID-influenza combination and standalone flu vaccines, the company reported on Monday (NASDAQ: MNDY ).
US FDA lifts clinical hold on Novavax's combo COVID-flu shot
The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines, the company said on Monday.
Novavax to Move Forward With Covid-19-Flu Vaccine After FDA Lifts Clinical Hold -- Update
Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, Sanofi will have the sole right to use Novavax's existing Covid-19 vaccine in combination with its own flu vaccine.
Novavax, Inc.: U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M adjuvant, today
FDA Lifts Clinical Hold On Novavax COVID-19-Influenza Combo Vaccine Candidate; Stock Up
Monday said the Food and Drug Administration or FDA has removed the clinical hold on its COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine candidates. Novavax shares were up more than 13 percent in pre-market.
Novavax Gets FDA Approval To Resume Testing Two Vaccines After Clinical Hold
Key Takeaways Novavax said the Food and Drug Administration allowed it to continue testing a combination COVID-19-flu and standalone flu vaccine that had been put on hold.Regulators stopped testing last month as one patient had a serious adverse event after taking the shot.
Novavax climbs as FDA lifts clinical hold on Covid, flu combo trials
Novavax (NVAX) shares surge 12% as FDA lifts clinical hold on COVID-19-Influenza Combination vaccine candidates.
Hosted on MSN4h
Novavax to Report Q3 Earnings: Here's What to Expect
Novavax NVAX is scheduled to report third-quarter 2024 earnings on Nov. 12, before the opening bell. In the last reported ...
BioPharma Dive2h
FDA lifts pause on Novavax flu vaccine trials
The Food and Drug Administration has cleared Novavax to move forward with testing of a combination vaccine for COVID-19 and ...
Novavax Q3 Earnings A Week Away - Time To Accept A New Reality
Besides Sanofi deal for nuvaxovid, Novavax has few opportunities to generate additional revenue, which likely means its stock ...
Nasdaq22d
How Bad Is This News for Novavax?
In early pandemic days, Novavax (NASDAQ: NVAX) shares soared as investors bet on the company's ability to bring a coronavirus vaccine to market. But as the biotech fell behind in the race and ...
Novavax, Inc. (NASDAQ:NVAX) Receives $17.83 Average Target Price from Analysts
Novavax, Inc. (NASDAQ:NVAX – Get Free Report) has been assigned an average rating of “Hold” from the six brokerages that are presently covering the company, Marketbeat.com reports. One research ...
Yahoo Finance25d
Novavax (NVAX) Advances While Market Declines: Some Information for Investors
In the latest market close, Novavax (NVAX) reached $10.35 ... On the other hand, the Dow registered a gain of 0.38%, and the technology-centric Nasdaq increased by 0.04%. Prior to today's trading ...
Nasdaq25d
Novavax Stock Falls After FDA Puts Two Vaccine Programs on Hold
Novavax was notified about the placing of ... with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 228 positions with double- and ...
Business Insider25d
Novavax’s Regulatory Setback and Mid-Term Underperformance: An Analyst’s Perspective
Novavax (NVAX) Company Description ... disease threats by using the proprietary recombinant nanoparticle vaccine technology. Its vaccine candidates include ResVax and NanoFlu.